BioPharma Dive October 10, 2024
Jonathan Gardner

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.

Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs.

Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound. But those two companies are already hard at work with successors of their own.

The next six months figure to be an important preview. Data are expected for a number of drugs that are already, or are shaping up to be, contenders in this high-stakes...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
How a breakthrough gene-editing tool will help the world cope with climate change
US drugmakers seek to curb reliance on China
The Top 5 Hurdles Facing the Biosimilars Market Right Now
Exclusive: Global summit blends AI and biotech
AI Points to Drug Repurposing Opportunities for Diseases Without Cures

Share This Article